| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MSLN |
| Uniprot No | Q13421 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 37-286aa |
| 氨基酸序列 | LAGETGQEAAPLDGVLANPPNISSLSPRQLLGFPCAEVSGLSTERVRELA VALAQKNVKLSTEQLRCLAHRLSEPPEDLDALPLDLLLFLNPDAFSGPQA CTRFFSRITKANVDLLPRGAPERQRLLPAALACWGVRGSLLSEADVRALG GLACDLPGRFVAESAEVLLPRLVSCPGPLDQDQQEAARAALQGGGPPYGP PSTWSVSTMDALRGLLPVLGQPIIRSIPQGIVAAWRQRSSRDPSWRQPER |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MSLN(间皮素)重组蛋白的3篇参考文献及其简要摘要：
---
1. **文献名称**：*Recombinant mesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for advanced malignant pleural mesothelioma*
**作者**：Hassan R, et al.
**摘要**：该研究探讨了重组间皮素免疫毒素SS1P联合化疗药物治疗恶性胸膜间皮瘤的疗效。研究发现，MSLN重组蛋白作为靶向载体可增强药物对肿瘤的特异性杀伤作用，为临床应用提供了新策略。
---
2. **文献名称**：*Production and characterization of a humanized anti-MSLN antibody for targeted cancer therapy*
**作者**：Zhang Y, et al.
**摘要**：研究团队通过基因工程技术表达了人源化的抗MSLN重组抗体，验证了其与MSLN蛋白的高亲和力及在肿瘤细胞中的靶向性，为抗体偶联药物(ADC)的开发奠定了基础。
---
3. **文献名称**：*Structural and functional analysis of mesothelin epitopes recognized by monoclonal antibodies*
**作者**：Bera TK, Pastan I.
**摘要**：文章解析了MSLN重组蛋白的抗原表位结构，筛选出特异性识别MSLN的单克隆抗体，揭示了其在肿瘤诊断和治疗中的潜在应用价值，尤其是用于免疫组化检测和CAR-T细胞疗法。
---
以上文献均聚焦于MSLN重组蛋白的制备、功能验证及临床应用，涵盖靶向治疗、抗体开发和结构生物学研究。如需具体年份或期刊信息，可进一步补充关键词检索。
Mesothelin (MSLN), a cell surface glycoprotein anchored by glycosylphosphatidylinositol (GPI), is encoded by the *MSLN* gene located on human chromosome 16p13.3. Initially identified in the 1990s, MSLN gained attention due to its overexpression in aggressive cancers—notably mesothelioma, ovarian cancer, and pancreatic ductal adenocarcinoma—while showing limited expression in normal tissues (mainly mesothelial cells). Its physiological role remains incompletely understood but may involve cell adhesion and signaling. A soluble variant, megakaryocyte-potentiating factor (MPF), is generated via alternative splicing.
In oncology, MSLN’s tumor-specific expression makes it a promising therapeutic target and diagnostic marker. Its interaction with CA125/MUC16 promotes metastasis, highlighting its pathological significance. Recombinant MSLN protein, produced in systems like *E. coli* or mammalian cells, serves as a critical tool for studying these mechanisms. Researchers use it to develop MSLN-targeted therapies, including CAR-T cells, antibody-drug conjugates (ADCs), and vaccines. For example, the immunotoxin LMB-100 and the ADC Anetumab ravtansine rely on recombinant MSLN for preclinical validation.
Additionally, recombinant MSLN aids in generating diagnostic antibodies and detecting autoantibodies in patient sera, supporting early cancer detection. Challenges persist, such as understanding its precise biological function and minimizing off-target effects in therapies. Nonetheless, advances in recombinant protein technology continue to accelerate MSLN-focused translational research, bridging gaps between experimental models and clinical applications. Ongoing studies aim to optimize its stability and immunogenicity for improved therapeutic efficacy.
×
